论文部分内容阅读
贫血是慢性肾衰(CRF)最常见的并发症,美国15万透析病人中贫血约占3/4。在促红细胞生成素(EPO)治疗前,透析病人平均红细胞压积为21～23%,约有25%病人需依赖输血,15%病人每月需输血一次以上。自从1989年6月美国食品与药品管理局批准使用EPO后,EPO便很快成为治疗CRF贫血的主要依靠,但EPO治疗后缺铁又成为最常见的问题之一,VanWyck等人报告,在EPO治疗中如果不给病人补铁,约有50%病人缺铁,这是由于EPO刺激机体利用铁合成新的红细胞之故,相对或绝对缺铁是EPO疗效差的一个最常见原因。转铁蛋白是第三种含量最丰富的血浆蛋白,正常血浆浓度为200～350mg/dl,由678个氨基酸组成,分子量75000
Anemia is the most common complication of chronic renal failure (CRF), and anemia in about 15,000 dialysis patients in the United States accounts for about three quarters. Prior to erythropoietin (EPO) treatment, dialysis patients had an average hematocrit of 21-23%, with about 25% requiring blood transfusions and 15% requiring blood transfusions more than once per month. EPO has quickly become a major reliance on the treatment of anemia of CRF since the FDA approved the use of EPO in June 1989. Iron deficiency after EPO has become one of the most common problems and Van Wyck et al. Reported that in the EPO About 50% of patients lack iron during treatment if they do not give iron to patients. This is because EPO stimulates the body to use iron to synthesize new red blood cells. Relative or absolute iron deficiency is one of the most common causes of poor efficacy of EPO. Transferrin is the third most abundant plasma protein with a normal plasma concentration of 200-350 mg / dl consisting of 678 amino acids with a molecular weight of 75,000